Home » Stocks » CBAY

CymaBay Therapeutics Inc. (CBAY)

Stock Price: $4.92 USD -0.19 (-3.72%)
Updated Mar 2, 2021 3:34 PM EST - Market open
Market Cap 347.23M
Revenue (ttm) n/a
Net Income (ttm) -64.65M
Shares Out 68.89M
EPS (ttm) -0.94
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 2
Last Price $4.92
Previous Close $5.11
Change ($) -0.19
Change (%) -3.72%
Day's Open 5.14
Day's Range 4.89 - 5.18
Day's Volume 964,771
52-Week Range 1.21 - 9.06

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 1 month ago

Here we discuss five biotech stocks - EDIT, VRTX, NTLA, CBAY, MRNS - that could prove to be great investments in the long run.

Other stocks mentioned: EDIT, MRNS, NTLA, VRTX
GlobeNewsWire - 3 months ago

NEWARK, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for ...

GlobeNewsWire - 3 months ago

NEWARK, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chro...

Seeking Alpha - 3 months ago

The FDA lifted all holds on all CymaBay liver disease studies back in July, since, shares have begun clawing back, +319% upside YTD. The company has presented positive top-line data from the E...

Seeking Alpha - 3 months ago

CymaBay Therapeutics (CBAY) CEO Sujal Shah on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 3 months ago

The AdventHealth Translational Research Institute (TRI) in Orlando, FL to lead the study, funded by the Helmsley Charitable Trust, evaluating MBX-2982, a GPR119 agonist, for its ability to inc...

GlobeNewsWire - 4 months ago

NEWARK, Calif., Oct. 30, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chro...

Zacks Investment Research - 5 months ago

Investors need to pay close attention to CymaBay Therapeutics (CBAY) stock based on the movements in the options market lately.

GlobeNewsWire - 6 months ago

NEWARK, Calif., Aug. 27, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies fo...

24/7 Wall Street - 6 months ago

While most of Wall Street focuses on large and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: APTX, EOLS, IBIO, SIEN
Seeking Alpha - 6 months ago

CymaBay Therapeutics, Inc.'s (CBAY) CEO Sujal Shah on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 6 months ago

NEWARK, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other ch...

24/7 Wall Street - 6 months ago

CymaBay Therapeutics Inc. (NASDAQ: CBAY) posted a huge gain to start the week after the company reported results from a late-stage clinical study for the treatment of primary biliary cholangit...

GlobeNewsWire - 7 months ago

Clinical hold lifted on seladelpar INDs in NASH, PBC and PSC 

GlobeNewsWire - 8 months ago

Data from previously completed open-label phase 2 study supports potential for seladelpar to improve pruritus (itching) in patients with PBC

Zacks Investment Research - 8 months ago

Investors need to pay close attention to CymaBay (CBAY) stock based on the movements in the options market lately.

The Motley Fool - 8 months ago

The development-stage company might be able to resume the development of its lead drug candidate, which was halted in late 2019.

GlobeNewsWire - 8 months ago

CymaBay Therapeutics, Inc. Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders CymaBay Therapeutics, Inc. Announces Change to Virtual Format for 2020 Annual Meeting of S...

Zacks Investment Research - 9 months ago

Reopening of the economy, vaccine hopes and stimulus measures helped Wall Street climb north in May and squash the old adage "sell in May and go away."

Other stocks mentioned: ALRN, EFOI, MRSN, MVIS
The Motley Fool - 9 months ago

A do-over on one of its drugs is a potential game-changer for CymaBay.

Zacks Investment Research - 9 months ago

CymaBay Therapeutics (CBAY) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Investment Research - 9 months ago

Investors need to pay close attention to CymaBay Therapeutics (CBAY) stock based on the movements in the options market lately.

Benzinga - 9 months ago

Non-alcoholic steatohepatitis biotechs are increasingly finding it difficult to make headway, and the lack of any approved therapy despite a slew of research is a testament to the challenge.

Other stocks mentioned: GNFT
24/7 Wall Street - 9 months ago

CymaBay Therapeutics Inc. (NASDAQ: CBAY) shares more than doubled on Tuesday after the company announced its first-quarter results, along with a corporate update.

Market Watch - 9 months ago

Shares of CymaBay Therapeutics Inc. CBAY, +123.91% rocketed on in very active morning trading Tuesday, after an upbeat report on results of a study of its treatment of liver disease prompted a...

Seeking Alpha - 9 months ago

CymaBay Therapeutics, Inc. (CBAY) CEO Sujal Shah on Q1 2020 Results - Earnings Call Transcript

InvestorPlace - 10 months ago

RBC Capital has peered into its crystal ball to reveal some of the market's most exciting biotech stocks. Here are seven that stand out.

Other stocks mentioned: ATRA, BHVN, MRNS, PTCT, SLDB, TBIO
Seeking Alpha - 11 months ago

CymaBay Therapeutics, Inc. (CBAY) CEO Sujal Shah on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 11 months ago

Investors need to pay close attention to CymaBay Therapeutics (CBAY) stock based on the movements in the options market lately.

GlobeNewsWire - 1 year ago

NEWARK, Calif., Jan. 29, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other ch...

Zacks Investment Research - 1 year ago

CymaBay Therapeutics, Inc. (CBAY) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Zacks Investment Research - 1 year ago

NASH sees a highly rewarding market with candidates of blockbuster potential. Let us take a look at the hits and misses in this space so far this year.

Other stocks mentioned: AGN, CNAT, GLMD, ICPT, MDGL
The Motley Fool - 1 year ago

Even in a winning market, these stocks fell. Find out why.

Other stocks mentioned: ACB, KL
The Motley Fool - 1 year ago

The company has halted the development of its lead drug candidate in one indication and terminated two other studies involving the compound.

Benzinga - 1 year ago

CymaBay Therapeutics Inc (NASDAQ: CBAY) shares are losing more than 75% of their value Monday after the company said it's halting the development of its lead drug, seladelpar.

Market Watch - 1 year ago

Shares of CymaBay Therapeutics Inc. CBAY, +6.12% are down 11% in premarket trading after the biopharmaceutical company ended two studies and halted a third for its experimental drug seladelpar.

Seeking Alpha - 1 year ago

Cymabay Therapeutics, Inc. (CBAY) CEO Sujal Shah on Q3 2019 Results - Earnings Call Transcript

The Motley Fool - 1 year ago

Investors will want to pay attention to what Assembly Biosciences, CymaBay Therapeutics, and Madrigal Pharmaceuticals say about their most promising candidate therapies.

Other stocks mentioned: ASMB, MDGL
GlobeNewsWire - 1 year ago

NEWARK, Calif., Oct. 14, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovati...

GlobeNewsWire - 1 year ago

NEWARK, Calif., Oct. 01, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY) today announced that two abstracts related to its seladelpar development program for the treatment ...

GlobeNewsWire - 1 year ago

NEWARK, Calif., Sept. 17, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovat...

GlobeNewsWire - 1 year ago

NEWARK, Calif., Sept. 03, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovat...

Seeking Alpha - 1 year ago

Primary Sclerosing Cholangitis is an orphan disease with no FDA approved therapeutic options or viable alternatives except surgical interventions.

Seeking Alpha - 1 year ago

Cymabay Therapeutics, Inc. (CBAY) CEO Sujal Shah on Q2 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Seladelpar is a specific, new generation PPAR-δ agonist in mid-late phase clinical development for NASH and cholestatic liver diseases, PBC and PSC.

Seeking Alpha - 1 year ago

CymaBay Therapeutics tumbled on reporting 12-week data from its phase 2b study using seladelpar to treat patients with nonalcoholic steatohepatitis.

24/7 Wall Street - 1 year ago

While most of Wall Street focuses on large and mega cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: BBCP, CVEO, ECA, TIVO
Zacks Investment Research - 1 year ago

CymaBay (CBAY) plummets as a phase IIb study on lead candidate, seladelpar, fails to show meaningful reductions in liver fat.

The Motley Fool - 1 year ago

Disappointing news and downbeat views hurt some stocks.

Other stocks mentioned: BYND, LOVE
The Motley Fool - 1 year ago

The company reported disappointing interim data from an ongoing phase 2b trial in NASH, but it wasn't all bad news.

About CBAY

CymaBay Therapeutics, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta, which has completed Phase II clinical study for the treatments of primary biliary cholangitis and sclerosing cholangitis, as well as patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, a selective orally-active G protein-coupled receptor ago... [Read more...]

Industry
Biotechnology
CEO
Sujal Shah
Employees
36
Stock Exchange
NASDAQ
Ticker Symbol
CBAY
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 11 analysts, the average rating for CBAY stock is "Strong Buy." The 12-month stock price forecast is 13.09, which is an increase of 166.06% from the latest price.

Price Target
$13.09
(166.06% upside)
Analyst Consensus: Strong Buy